Journal of Medical Internet Research (Jun 2023)

Patient Engagement in a Multimodal Digital Phenotyping Study of Opioid Use Disorder

  • Cynthia I Campbell,
  • Ching-Hua Chen,
  • Sara R Adams,
  • Asma Asyyed,
  • Ninad R Athale,
  • Monique B Does,
  • Saeed Hassanpour,
  • Emily Hichborn,
  • Melanie Jackson-Morris,
  • Nicholas C Jacobson,
  • Heather K Jones,
  • David Kotz,
  • Chantal A Lambert-Harris,
  • Zhiguo Li,
  • Bethany McLeman,
  • Varun Mishra,
  • Catherine Stanger,
  • Geetha Subramaniam,
  • Weiyi Wu,
  • Christopher Zegers,
  • Lisa A Marsch

DOI
https://doi.org/10.2196/45556
Journal volume & issue
Vol. 25
p. e45556

Abstract

Read online

BackgroundMultiple digital data sources can capture moment-to-moment information to advance a robust understanding of opioid use disorder (OUD) behavior, ultimately creating a digital phenotype for each patient. This information can lead to individualized interventions to improve treatment for OUD. ObjectiveThe aim is to examine patient engagement with multiple digital phenotyping methods among patients receiving buprenorphine medication for OUD. MethodsThe study enrolled 65 patients receiving buprenorphine for OUD between June 2020 and January 2021 from 4 addiction medicine programs in an integrated health care delivery system in Northern California. Ecological momentary assessment (EMA), sensor data, and social media data were collected by smartphone, smartwatch, and social media platforms over a 12-week period. Primary engagement outcomes were meeting measures of minimum phone carry (≥8 hours per day) and watch wear (≥18 hours per day) criteria, EMA response rates, social media consent rate, and data sparsity. Descriptive analyses, bivariate, and trend tests were performed. ResultsThe participants’ average age was 37 years, 47% of them were female, and 71% of them were White. On average, participants met phone carrying criteria on 94% of study days, met watch wearing criteria on 74% of days, and wore the watch to sleep on 77% of days. The mean EMA response rate was 70%, declining from 83% to 56% from week 1 to week 12. Among participants with social media accounts, 88% of them consented to providing data; of them, 55% of Facebook, 54% of Instagram, and 57% of Twitter participants provided data. The amount of social media data available varied widely across participants. No differences by age, sex, race, or ethnicity were observed for any outcomes. ConclusionsTo our knowledge, this is the first study to capture these 3 digital data sources in this clinical population. Our findings demonstrate that patients receiving buprenorphine treatment for OUD had generally high engagement with multiple digital phenotyping data sources, but this was more limited for the social media data. International Registered Report Identifier (IRRID)RR2-10.3389/fpsyt.2022.871916